Thank you skezan and Riz. Regardless the level of CCR5 overexpression between TNBC and CRC, I am confident the CRC trial was coordinated with KOL and will prove success. While CCR5 is obviously important for leronlimab, the elegant ability of macrophage repolarization and PD-L1 cold-to-hot MOA will prove successful in CRC (and many other cancers) IMO.
(6)
(0)
CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.